CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...
Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...
Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell ...
Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.
The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.
The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo ...
Zacks Investment Research on MSN4d
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCCBristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...
Pharmaceutical Technology on MSN4d
EC approves BMS’ Opdivo and Yervoy combo for HCCThe European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the ...
An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.
The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant ...
Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer. Bristol Myers on Friday ...
Squibb announced that the European Commission has approved Opdivo plus Yervoy for the first-line treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback